TORL Biotherapeutics LLC announced that it will receive $158,300,000 in funding on April 4, 2024. The company will issue membership units in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.01 USD | -0.81% | -3.61% | -16.01% |
02:34pm | Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab | MT |
01:32pm | Bristol Myers: deadline set for subcutaneous Opdivo | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.01% | 87.9B | |
+38.86% | 705B | |
+32.98% | 583B | |
-3.11% | 364B | |
+21.15% | 332B | |
+6.09% | 291B | |
+16.11% | 238B | |
-3.56% | 210B | |
+10.49% | 209B | |
+9.58% | 169B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- TORL BioTherapeutics LLC announced that it expects to receive $158.3 million in funding